Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200320112> ?p ?o ?g. }
- W4200320112 abstract "Abstract Background Myasthenia gravis is a neuromuscular autoimmune disorder characterized by weakness and disability in the voluntary muscles. There have been several preliminary studies on the epidemiology of myasthenia gravis in different parts of the world and the effectiveness of common drugs in its treatment, but there has been no comprehensive study of the efficacy of common drugs in the treatment of myasthenia gravis. Therefore, this study aimed to determine the epidemiology of myasthenia gravis globally and the effectiveness of common drugs in its treatment using systematic review and meta-analysis. Methods Research studies were extracted from IranDoc, MagIran, IranMedex, SID, ScienceDirect, Web of Sciences (WoS), ProQuest, Medline (PubMed), Scopus and Google Scholar based on Cochran's seven-step guidelines using existing keywords extracted in MeSH browser. The I 2 test was used to calculate the heterogeneity of studies, and Begg and Mazumdar rank correlation tests were used to assess publication bias. Data were analyzed using Comprehensive Meta-Analysis software (Version 2). Results In the search for descriptive studies based on the research question, 7374 articles were found. After deleting articles unrelated to the research question, finally, 63 articles with a sample size of 1,206,961,907 people were included in the meta-analysis. The prevalence of MG worldwide was estimated to be 12.4 people (95% CI 10.6–14.5) per 100,000 population. For analytical studies on the effectiveness of common myasthenia gravis drugs, 4672 articles were found initially, and after removing articles unrelated to the research question, finally, 20 articles with a sample size of 643 people in the drug group and 619 people in the placebo group were included in the study. As a result of the combination of studies, the difference between the mean QMGS score index after taking Mycophenolate and Immunoglobulin or plasma exchange drugs in the group of patients showed a significant decrease of 1.4 ± 0.77 and 0.62 ± 0.28, respectively (P < 0.01). Conclusion The results of systematic review of drug evaluation in patients with myasthenia gravis showed that Mycophenolate and Immunoglobulin or plasma exchange drugs have positive effects in the treatment of MG. It also represents the positive effect of immunoglobulin or plasma exchange on reducing SFEMG index and QMGS index and the positive effect of Mycophenolate in reducing MG-ADL index, SFEMG and Anti-AChR antibodies index. In addition, based on a meta-analysis of the random-effect model, the overall prevalence of MG in the world is 12.4 people per 100,000 population, which indicates the urgent need for attention to this disease for prevention and treatment." @default.
- W4200320112 created "2021-12-31" @default.
- W4200320112 creator A5010745136 @default.
- W4200320112 creator A5012637279 @default.
- W4200320112 creator A5029879204 @default.
- W4200320112 creator A5037222625 @default.
- W4200320112 creator A5038806163 @default.
- W4200320112 creator A5068110088 @default.
- W4200320112 creator A5068423661 @default.
- W4200320112 creator A5072734024 @default.
- W4200320112 date "2021-12-01" @default.
- W4200320112 modified "2023-09-26" @default.
- W4200320112 title "Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis" @default.
- W4200320112 cites W102673934 @default.
- W4200320112 cites W1527112336 @default.
- W4200320112 cites W1568142966 @default.
- W4200320112 cites W1585785281 @default.
- W4200320112 cites W163003246 @default.
- W4200320112 cites W1645572349 @default.
- W4200320112 cites W1646480581 @default.
- W4200320112 cites W1647526924 @default.
- W4200320112 cites W1661216026 @default.
- W4200320112 cites W1697764196 @default.
- W4200320112 cites W1852210946 @default.
- W4200320112 cites W1869564459 @default.
- W4200320112 cites W187753557 @default.
- W4200320112 cites W1897013744 @default.
- W4200320112 cites W1965544843 @default.
- W4200320112 cites W1971022805 @default.
- W4200320112 cites W1971687100 @default.
- W4200320112 cites W1971690756 @default.
- W4200320112 cites W1971910396 @default.
- W4200320112 cites W1972329861 @default.
- W4200320112 cites W1972803812 @default.
- W4200320112 cites W1976928494 @default.
- W4200320112 cites W1977231670 @default.
- W4200320112 cites W1980271590 @default.
- W4200320112 cites W1983404333 @default.
- W4200320112 cites W1985124329 @default.
- W4200320112 cites W1985174308 @default.
- W4200320112 cites W1985409025 @default.
- W4200320112 cites W1986290994 @default.
- W4200320112 cites W1991110217 @default.
- W4200320112 cites W1994741956 @default.
- W4200320112 cites W2000639824 @default.
- W4200320112 cites W2001447887 @default.
- W4200320112 cites W2002284795 @default.
- W4200320112 cites W2007260704 @default.
- W4200320112 cites W2009061035 @default.
- W4200320112 cites W2010900400 @default.
- W4200320112 cites W2014691590 @default.
- W4200320112 cites W2015017080 @default.
- W4200320112 cites W2020685420 @default.
- W4200320112 cites W2021018822 @default.
- W4200320112 cites W2021441723 @default.
- W4200320112 cites W2023275299 @default.
- W4200320112 cites W2023966881 @default.
- W4200320112 cites W2024831324 @default.
- W4200320112 cites W2024842301 @default.
- W4200320112 cites W2025558091 @default.
- W4200320112 cites W2027716010 @default.
- W4200320112 cites W2032101724 @default.
- W4200320112 cites W2032492876 @default.
- W4200320112 cites W2034608961 @default.
- W4200320112 cites W2035940112 @default.
- W4200320112 cites W2039449701 @default.
- W4200320112 cites W2043526835 @default.
- W4200320112 cites W2043582430 @default.
- W4200320112 cites W2046894023 @default.
- W4200320112 cites W2047088157 @default.
- W4200320112 cites W2047193332 @default.
- W4200320112 cites W2049792271 @default.
- W4200320112 cites W2051200447 @default.
- W4200320112 cites W2053680723 @default.
- W4200320112 cites W2055588359 @default.
- W4200320112 cites W2056517818 @default.
- W4200320112 cites W2058924245 @default.
- W4200320112 cites W2059716117 @default.
- W4200320112 cites W2066136508 @default.
- W4200320112 cites W2066571580 @default.
- W4200320112 cites W2068819673 @default.
- W4200320112 cites W2069263247 @default.
- W4200320112 cites W2069952320 @default.
- W4200320112 cites W2072475795 @default.
- W4200320112 cites W2073189685 @default.
- W4200320112 cites W2078508152 @default.
- W4200320112 cites W2081170156 @default.
- W4200320112 cites W2086132474 @default.
- W4200320112 cites W2087294716 @default.
- W4200320112 cites W2087360608 @default.
- W4200320112 cites W2089618665 @default.
- W4200320112 cites W2092230365 @default.
- W4200320112 cites W2093346948 @default.
- W4200320112 cites W2093551345 @default.
- W4200320112 cites W2101367658 @default.
- W4200320112 cites W2102593255 @default.
- W4200320112 cites W2102703420 @default.
- W4200320112 cites W2106877245 @default.
- W4200320112 cites W2108526545 @default.
- W4200320112 cites W2108643233 @default.